This activity is intended for primary care physicians.

At the conclusion of this activity, participants should be able to:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the sponsorship of National Jewish Medical and Research Center's Office of Professional Education. National Jewish Medical and Research Center is accredited by the ACCME to provide continuing medical education for physicians.

National Jewish Medical and Research Center designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Mark Boguniewicz, MD
Professor
Division of Pediatric Allergy and Immunology
Department of Pediatrics
National Jewish Medical and Research Center
University of Colorado School of Medicine
Denver, CO

Donald Y. M. Leung, MD, PhD
Edelstein Family Chair, Pediatric Allergy and Immunology
National Jewish Medical and Research Center
Professor of Pediatrics
University of Colorado School of Medicine
Denver, Colorado

Noreen Heer Nicol, MS, RN, FNP
Chief Clinical Officer/Chief Nursing Officer
National Jewish Medical and Research Center
Clinical Senior Instrructor
University of Colorado Schoool of Nursing
Denver, Colorado

Bryn Salt, MD
Fellow, Division of Pediatric Allergy and Immunology
Department of Pediatrics
National Jewish Medical and Research Center
Denver, Colorado

All faculty in a position to control the content of this activity are expected to disclose any or no significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.

Significant financial interest is defined as receiving, or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit.

Key

± Research Grant

^ Consultant

~ Speakers' Bureau

> Other (eg clinical study)

Mark Boguniewicz, MD
± > Novartis, Inc.
± Astellas Pharma, Inc., Sinclair Pharma, PLC.
^ Alza Corporation, Chester Valley Pharmaceuticals, Inc.

David Beuther, MD
Merck & Co., Inc.

Ronina Covar, MD
^ AstraZeneca, Merck & Co., Inc.
± AstraZeneca, Ross Products/Abbott Laboratories

Stephen K. Frankel, MD
Has no significant financial interest to report

Allidah Hicks, RN, MS
Has no significant financial interest to report

Donald Leung, MD
± ^ ~ Novartis, Genentech

Harold Nelson, MD
National Jewish Medical and Research Center
^ Curalogic, Dey Laboratories, Dynavax Technologies, Genentech,
GlaxoSmithKline, Johnson & Johnson, Novartis, Schering Plough (Integrated Therapeutics Group)
~ AstraZeneca, GlaxoSmithKline
± Boehringer, Clinical Therapeutics, Genentech, MediciNova, Inc., Sepracor,
Inc., Novartis, Schering Plough (Integrated Therapeutics Group), Teva Pharmaceutical Industries Ltd., Wyeth

Noreen Nicol, MS, RN, FNP
~ Astellas Pharma, Inc., Novartis, Unilever
> Other - Advisory Board, Chester Valley Pharmaceuticals, Inc.
^ Ferndale Labs, Unilever

Bryn Salt, MD
No significant financial interest

Richard W. Weber, MD
^ AstraZeneca, Genentech/Novartis
~ AstraZeneca, Genentech/Novartis, GlaxoSmithKline
± Eli Lilly and Company, GlaxoSmithKline, MannKind Corporation, Pfizer, Inc.

This activity is funded by an educational grant from Novartis, Inc.